Navigation Links
Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
Date:3/3/2008

d be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGFβ3) and GA-GCB (velaglucerase alfa); manufacturing and commercialization including, but not limited to, the launch and establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not limited to, the impact of those on Shire's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
2. DW Healthcare Partners Announces the Sale of Tandem Labs
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
5. MarketResearch.com Announces Distribution of Spectra Intelligence Research
6. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
7. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
8. Wyeth Announces Executive Change in Finance Organization
9. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
10. Pharmacopeia Announces Management Team Changes
11. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 OncLive® is ... Center has joined its Strategic Alliance Partnership program. ... Partnership program, UNC Lineberger will have the opportunity ... awareness of its cutting-edge research initiatives, community-directed cancer ... Lineberger will work with OncLive to educate their ...
(Date:7/23/2014)... July 23, 2014 Adult stem ... therapies are biological, but not magical. However, ... to treat them as if they were magical. ... unsanctioned studies that constitute “stem cell tourism,” are ... approach to developing new regenerative medicine therapies. In ...
(Date:7/22/2014)... 2014 (PRWEB) July 23, 2014 ... University. , The goal of the Symposium ... full spectrum of scientists working in the biomaterials ... topics that represent the most promising directions for ...     Provide faculty and government scientists ...
(Date:7/22/2014)... Even within a phylum so full of mean little ... arthropods for its cruelty -- at least to crickets. Native ... is a most predatory sort of parasite. It swoops onto ... of larvae, and leaves its wicked brood to invade, kill ... of this would be possible without the fly,s ability to ...
Breaking Biology Technology:OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4
... , June 15 /PRNewswire-Asia/ -- AgFeed Industries, Inc. ... hog production and animal nutrient companies in China , ... the first phase of the Xinyu production pod starting in ... a division of Genus PLC (LSE: GNS). This stocking will ...
... Cellular ... of bringing more relevant and highly predictive toxicity testing to the drug discovery process. ... Madison, ... into a research collaboration with the goal of bringing more relevant and highly predictive ...
... ... the life sciences industry that incorporates distinctive features and functionality , ... (PRWEB) June 15, ... life sciences industry, today announced the release of Version 2.0 of its Interactive ...
Cached Biology Technology:AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod 2AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod 3AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod 4Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity 2Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity 3Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 2Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 3
(Date:7/23/2014)... Currently, no cure exists for Alzheimer,s disease, the ... Americans. But scientists are now reporting new progress ... cancer treatment, that shows promise as a potential ... ACS, Journal of Medicinal Chemistry . , ... that in a healthy brain, the protein known ...
(Date:7/23/2014)... preconditioning has been confirmed by many studies, but ... released in the Neural Regeneration Research ... and co-workers from Tongji Hospital Affiliated to Tongji ... China performed cerebral ischemic preconditioning in rats by ... mechanism underlying the neuroprotective effect of ischemic preconditioning. ...
(Date:7/22/2014)... The exhibit consists of both still images and ... of scientific research. Forty-four still images were chosen ... students, postdocs, staff, and alumni representing more than ... from more than 50 submissions. , Zach Donnell, ... of the 2014 organizers, noted that the exhibit ...
Breaking Biology News(10 mins):Art of Science 2014 2
... 16, 2010 Primary care physicians agree they have a ... the right weight management resources. Obese or heavier adults ... lose weight may lack information about effective weight loss methods ... research commissioned and released today by the Strategies to Overcome ...
... programs to safeguard them from getting out of control ... cancer. Until now, researchers assumed that these protective systems ... first time, using an animal model for lymphoma, cancer ... the Charit University Hospital Berlin in Germany have ...
... to passive smoking are more likely to have health problems ... levels of nucleated red blood cells in the umbilical cord ... and Public Health . Pediatrician Abd ElBaky of the ... Cairo University, Egypt, have found that obesity and passive smoking ...
Cached Biology News:STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 2STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 32 at 1 stroke -- how cells protect themselves from cancer 2Obesity and passive smoking reduce oxygen supply to unborn baby 2
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: